September quarter profit rises; review highlights German subsidiary exposure

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionEmphasis Of MatterResults View source PDF Explain this filing

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.5%Reaction day

₹1469.00

prior close

₹1510.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.7%-7.2% vs market

Pharmaceuticals peers, median of 173sector+2.0%-7.4% vs sector

On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 7.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.6

10m

-0.8

15m

-2.5

30m

-2.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.5+1.7-7.2+2.0-7.4

Next day

-9.1pendingpending+2.6-11.7

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Unaudited standalone and consolidated results were approved for the quarter and six months ended September 30, 2026. Standalone revenue rose 13.6% to Rs218.76 crore in the quarter and 20.6% to Rs397.55 crore for the half year. Standalone half-year net profit rose 75.9% to Rs54.46 crore. The review highlights Rs28.60 crore of pending share application money at financially challenged German subsidiary Venus Pharma GmbH; it was not qualified.

Likely market impact

Results are positive for shareholders, but Rs28.60 crore of German subsidiary exposure and needed parent support create recovery risk.